From bench to bedside: A diagnostics framework for pharmacogenetics research

Molecular Genetics and Metabolism

Volumn 77, Issue 1-2, 2002, Pages 57-60

  Katz, David A ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Clinical applications; Genotype phenotype correlations; Molecular diagnostics; Pharmacogenetics

Indexed keywords

AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ARACHIDONATE 5 LIPOXYGENASE; ATRELEUTON; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROURACIL; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; LIPOXYGENASE INHIBITOR; TRASTUZUMAB; UNCLASSIFIED DRUG;

ALLELE; ASTHMA; BREAST CARCINOMA; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFECT; DRUG RESPONSE; ENZYME INHIBITION; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENETIC PROCEDURES; GENETIC VARIABILITY; GENOTYPE; HUMAN; LIVER; PHARMACOGENETICS; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; TISSUE LEVEL; TREATMENT INDICATION; VALIDATION PROCESS; GENETICS; METHODOLOGY; PROTO ONCOGENE;

ARACHIDONATE 5-LIPOXYGENASE; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROMOTER REGIONS (GENETICS); RESEARCH DESIGN;

EID: 0036396897     PISSN: 10967192     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1096-7192(02)00143-9     Document Type: Review

References (21)

1. A. Garrod, The incidence of alkaptonuria: a study in chemical individuality, Lancet (1902) 1616-1620.
2. P. Carson, C. Flanagan, C. Ickes, A. Alving, Enzymatic deficiancy in primaquine-sensitive erythrocytes, Science 124 (1956) 484-485.
3. H. Lehmann, The familial incidence of low pseudocholinesterase level, Lancet (1956).
4. D. Price Evans, K. Manley, V. McKusick, Genetic control of isoniazid metabolism in man, British Medical Journal (1960) 485-491.
5. Food and Drug Administration, Substantially Equivalent 510(k) Device Information for Trugene HIV-1 Genotyping Kit, Bethesda, MD, 2002. Available from http://www.fda.gov/cber/seltr/K000038L.htm.
6. Food and Drug Administration, PathVysion; HER-2 DNA Probe Kit, Bethesda, MD, 2001. Available from http://www.fda.gov/cdrh/pdf/p980024s001.html.
7. Food and Drug Administration, Premarket Approval Decision for DAKO HercepTest, Bethesda, MD, 1998. Available from http://www.fda.gov/cdrh/pma/pmasep98.html.
8. R. Weinshilboum, Thiopurine methyltransferase pharmacogenetics, Pharmaceutical News 7 (6) (2000) 19-25.
9. J. Drazen, B. Gaston, S. Shore, Chemical regulation of pulmonary airway tone, Annual Review of Physiology 57 (1995) 151-170.
10. Food and Drug Administration, Label for Zy.o(TM) Filmtab, Bethesda, MD, 2000. Available from http://www.fda.gov/cder/foi/label/2001/20471s8lbl.pdf.
11. K. In, K. Asano, D. Beier, J. Grobholz, P. Finn, E. Silverman, et al., Naturally occurring mutations in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription, Journal of Clinical Investigation 99 (1997) 1130-1137.
12. J. Drazen, C. Yandava, L. Dubé, N. Szczerback, R. Hippensteel, A. Pillari, et al., Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment, Nature Genetics 22 (2) (1999) 168-170.
13. American Thoracic Society, Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma, American Review of Respiratory Diseases 136 (1987) 225-244.
14. D. Slamon, G. Clark, S. Wong, W. Levin, A. Ullrich, W. McGuire, Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene, Science 235 (1987) 177-182.
15. P. Carter, L. Presta, C. Gorman, J. Ridgway, D. Henner, W. Wong, et al., Humanization of an anti-p185 HER2 antibody for human cancer therapy, Proceedings of the National Academy of Sciences USA 89 (1992) 4285-4289.
16. C. Vogel, E.cacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer, Journal of Clinical Oncology 20 (3) (2002) 719-726.
17. D. Slamon, B. Leyland-Jone, S. Shak, H. Fuchs, V. Paton, A. Bajamonde, et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New England Journal of Medicine 344 (11) (2001) 783-792.
18. Dressler L, Berry D, LiuE, Cowan D, Broadwater G, Tse J, et al., Amplification of ErbB2 by fluorescent in situ hybridization (FISH): an alternate method to predict outcome following doseescalated CAF in stage II, node positive breast cancer patients. A Cancer and Leukemia Group B (CALGB) study, vol. 81, American Society of Clinical Oncology Program Proceedings, 1999, abstract 281. Available from http://www.asco.org/prof/me/html/99abstracts/bc/m_281.htm.
19. NCCLS, MM1-A molecular diagnostic methods for genetic diseases; approved guideline. Available from http://www.nccls.org.
20. NCCLS, EP21-P estimation of total analytical error for clinical laboratory methods; proposed guideline. Available from http://www.nccls.org.
21. J. Westgard, Six Sigma Quality Design and Control, Westgard QC, Inc., Madison, WI, 2001.